WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
